StockData
Immix Biopharma, Inc. logo

Immix Biopharma, Inc. (IMMX) stock

IMMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.11−0.09 (-1.25%)

Close on Nov 18, 2026Market cap $508.64MP/E –Yield –

Immix Biopharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Immix Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$41.82M. For fiscal 2025 it was -$29.96M. The highest annual figure on record is -$453.85K in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$29.96M–
FY2024Dec 31, 2024-$22.67M–
FY2023Dec 31, 2023-$16.14M–
FY2022Dec 31, 2022-$8.22M–
FY2021Dec 31, 2021-$1.35M–
FY2020Dec 31, 2020-$453.85K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.46M–
Q1 FY2026Mar 31, 2026-$10.80M–
Q4 FY2025Dec 31, 2025-$10.89M–
Q3 FY2025Sep 30, 2025-$7.66M–
Q2 FY2025Jun 30, 2025-$6.72M–
Q1 FY2025Mar 31, 2025-$4.68M–
Q4 FY2024Dec 31, 2024-$4.99M–
Q3 FY2024Sep 30, 2024-$7.39M–
Q2 FY2024Jun 30, 2024-$4.70M–
Q1 FY2024Mar 31, 2024-$5.59M–
Q4 FY2023Dec 31, 2023-$5.38M–
Q3 FY2023Sep 30, 2023-$4.52M–
Q2 FY2023Jun 30, 2023-$3.72M–
Q1 FY2023Mar 31, 2023-$2.52M–
Q4 FY2022Dec 31, 2022-$3.79M–
Q3 FY2022Sep 30, 2022-$1.53M–
Q2 FY2022Jun 30, 2022-$1.56M–
Q1 FY2022Mar 31, 2022-$1.33M–
Q4 FY2021Dec 31, 2021-$598.34K–
Q3 FY2021Sep 30, 2021-$347.99K–
Q2 FY2021Jun 30, 2021-$243.17K–
Q1 FY2021Mar 31, 2021-$162.52K–

More Immix Biopharma figures

See a number that looks wrong?